Alantra Private Equity strengthens AIVORIQ with two new acquisitions and consolidates one of Spain’s leading dental laboratory groups
Date 15 June 2026
Type Alternative Asset Management
- Alantra PE, through its portfolio company AIVORIQ, has acquired two additional dental laboratories, bringing the group to more than 20 laboratories across Spain.
- Since Alantra PE’s initial investment in 2024, AIVORIQ has grown into a nationwide platform with close to €40mn in revenues.
- The group is progressing with its buy-and-build strategy in Spain, while laying the foundations for future international expansion.
Madrid, 15 June 2026 – Alantra Private Equity, through its dental laboratory platform AIVORIQ, has completed the acquisition of two additional dental laboratories, further consolidating one of the leading dental laboratory groups in Spain.
The acquisitions reinforce AIVORIQ’s nationwide footprint and strengthen its capabilities in fixed prosthetics, aesthetic treatments, and orthodontics. The newly acquired laboratories primarily serve independent dental clinics and bring advanced digital capabilities that support more precise design processes, improved turnaround times, and enhanced service quality for dentists and patients.
AIVORIQ has grown significantly since Alantra PE launched the project. The group now comprises more than 20 dental laboratories across Spain, with close to €40mn in revenues. This growth has been driven through a combination of strong double-digit organic growth and the successful execution of its buy-and-build strategy in a highly fragmented market.
The Spanish dental laboratory sector remains highly fragmented, with thousands of independent operators and significant scope for consolidation. AIVORIQ’s strategy is focused on building a scalable, integrated, and technology-enabled platform capable of offering high-quality services to dental clinics while preserving the entrepreneurial expertise of the laboratories that join the group.
As part of the transaction, the owners of the acquired laboratories have reinvested in AIVORIQ and will remain involved in the project, aligning their interests with the group’s next stage of growth. This model has been a key element of AIVORIQ’s success, ensuring that the founders of the laboratories integrated to date continue to participate in the project.
The group expects to continue expanding its platform in Spain, with the objective of reaching c. 30 laboratories. In parallel, AIVORIQ is preparing for a potential next phase of international growth, exploring opportunities in European markets such as the United Kingdom, Germany, and Italy. The company is also advancing industrial and technological initiatives to enhance productivity, service quality, and scalability.
Ángel Manotas, Managing Director of Alantra Private Equity, said: “The evolution of AIVORIQ demonstrates the strength of our buy-and-build strategy in a fragmented and resilient healthcare market. The platform has achieved significant scale, continues to grow above the market, and is increasingly well positioned for its next phase of development, both in Spain and internationally.”
Alantra PE was advised by EY Abogados.
